An experimental medicine for patients with polycythemia vera, a rare blood cancer, has met is primary endpoint in a global Phase 3 trial conducted by Novartis. The treatment Jakavi (ruxolitinib) is an inhibitor of the JAK 1 and JAK 2 tyrosine kinases.
